Zevra Therapeutics (ZVRA) Proxy filing summary

Executive summary

• Achieved $106.5 million in net revenue for 2025, with $87.4 million from MIPLYFFA, reaching over 40% of diagnosed NPC patients in the U.S. in its first full year of commercialization.

• Advanced global pipeline, including EU Marketing Authorization Application for arimoclomol and progress in the Phase 3 DISCOVER trial of celiprolol.

• Generated $150 million from the sale of a Rare Pediatric Disease Priority Review Voucher, supporting operations and growth.

• Strengthened leadership with key appointments, including a new CFO and a new board member with rare disease expertise.

• Relocated headquarters to Boston to enhance access to biotech talent and partnerships.

Voting matters and shareholder proposals

• Election of two Class II directors to serve until the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Approval of an amendment to phase out the classified board structure, moving to annual director elections starting in 2027.

Board of directors and corporate governance

• Board consists of eight members, with 87.5% independence and diverse backgrounds in leadership, finance, and industry.

• Board Chair and CEO roles are separated to reinforce independence.

• Board regularly reviews governance practices and conducts annual performance reviews.

• Board committees (Audit, Compensation, Nominating & Corporate Governance) are fully independent.

• Board composition includes 25% women and 25% from underrepresented communities.